BackGuardant Health Overview
Guardant Health Inc

Guardant Health Target Price

Analysts' average 12-month price target for Guardant Health is $180.

Get informed when a big investor buys or sells

+ Follow

Share Price

$161.04

Average Target Price

$180.7712.3% upside

26 analysts in the last 4 months

High: $210 | Low: $127

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-04Morgan Stanley$18514.9% upsideOpen
2026-08-04Stephens$19521.1% upsideOpen
2026-08-04Piper Sandler$19319.8% upsideOpen
2026-07-31RBC CapitalDan Leonard$20024.2% upsideOpen
2026-07-31RBC Capital$21030.4% upsideOpen
2026-07-31Stifel NicolausDaniel Arias$18011.8% upsideOpen
2026-07-31Goldman Sachs$21030.4% upsideOpen
2026-07-31Mizuho SecuritiesAnthony Petrone$20024.2% upsideOpen
2026-07-31BTIGMark Massaro$19521.1% upsideOpen
2026-07-31Barclays$20024.2% upsideOpen
2026-07-16Guggenheim$19018% upsideOpen
2026-07-14Canaccord GenuityKyle Mikson$20527.3% upsideOpen
2026-07-09Morgan Stanley$1758.7% upsideOpen
2026-07-06Evercore ISIVijay Kumar$20024.2% upsideOpen
2026-07-02BernsteinEve Burstein$20024.2% upsideOpen
2026-07-01BTIG$19018% upsideOpen
2026-06-29Guggenheim$1600.6% downsideOpen
2026-06-24UBS$1506.9% downsideOpen
2026-06-11RBC CapitalDan Leonard$18514.9% upsideOpen
2026-06-08Mizuho Securities$1758.7% upsideOpen
2026-06-05Goldman SachsEvie Koslosky$1652.5% upsideOpen
2026-06-02Evercore ISI$1600.6% downsideOpen
2026-05-27BTIG$1600.6% downsideOpen
2026-05-26BTIGMark Massaro$1553.8% downsideOpen
2026-05-21Piper Sandler$12721.1% downsideOpen
2026-05-12Piper SandlerDavid Westenberg$13516.2% downsideOpen
2026-04-14BarclaysLuke Sergott$11528.6% downsideOpen
2026-02-24Piper Sandler$13019.3% downsideOpen
2026-02-23Raymond James$12919.9% downsideOpen
2026-02-20Evercore ISI$11031.7% downsideOpen
2026-02-20BTIG$14510% downsideOpen
2026-02-20Stifel Nicolaus$13019.3% downsideOpen
2026-02-20Canaccord Genuity$13516.2% downsideOpen
2026-02-20Barclays$13019.3% downsideOpen
2026-02-17Robert W. BairdCatherine Schulte$12025.5% downsideOpen
2026-01-30UBS$1758.7% upsideOpen
2026-01-26Guggenheim$13516.2% downsideOpen
2026-01-09Stifel Nicolaus$12025.5% downsideOpen
2026-01-09Mizuho Securities$13516.2% downsideOpen
2026-01-05GuggenheimSubbu Nambi$11528.6% downsideOpen
2026-01-05Evercore ISIVijay Kumar$10534.8% downsideOpen
2025-12-22Canaccord Genuity$12522.4% downsideOpen
2025-12-17Mizuho Securities$12025.5% downsideOpen
2025-12-15Leerink Partners$1553.8% downsideOpen
2025-12-15Wells FargoBrandon Couillard$12025.5% downsideOpen
2025-12-15Barclays$12025.5% downsideOpen
2025-12-12BTIG$14013.1% downsideOpen
2025-12-01Morgan StanleyTejas Savant$13019.3% downsideOpen
2025-10-30UBSDan Leonard$11031.7% downsideOpen
2025-10-30BTIGMark Massaro$10037.9% downsideOpen

Guardant Health (GH) FAQ

The latest target price for GH is $180. Investors often review this figure alongside Guardant Health's historical trend and sector peers before judging valuation or financial health.

Guardant Health trades near $161.04 while the consensus target sits at $180 (12.3% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting GH's target price ($180), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Guardant Health's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.